Article | September 21, 2022

Ensuring Clinical Trial Data Integrity: Five Things To Remember When Selecting a CRO Partner

GettyImages-1134462016 CRO agility

In September 2021, the FDA issued a notification to the biopharmaceutical industry alerting them that multiple clinical studies conducted by two India-based CROs were “not acceptable” because of data integrity concerns.

Following inspections conducted in 2019 at the CROs’ facilities in India, as well as analyses of study data generated by them, which were used in “several applications,” the FDA determined that data from the two CROs are “not acceptable to support a determination of safety or effectiveness for brand name drugs, or to show affected generic products are bioequivalent to brand name products.” In fact, the FDA asked sponsors that conducted trials at the two India-based CROs to redo bioequivalence/bioavailability studies essential for regulatory approval, noting that the action is part of the FDA’s “continued vigilance and commitment to data integrity and protecting consumers from products that may put them at risk.”

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader

Bioforum the Data Masters Inc.